Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Tafamidis meglumine

Known as: D-Glucitol, 1-Deoxy-1-(Methylamino)-, 2-(3,5-Dichlorophenyl)-6-Benzoxazolecarboxylate (1:1), D-Gluco-2,3,4,5,6-Pentahydroxy-N-Methylhexan-1-Aminium 2-(3,5-Dichlorophenyl)Benzoxazole-6-Carboxylate 
A soft gelatin capsule formulation containing the meglumine salt form of tafamidis, a small molecule and pharmacological chaperone with potential… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

Fx-1006A
TAFAMIDIS MEGLUMINE 20 mg ORAL CAPSULE [Vyndaqel]tafamidis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy
To better characterize the effects of tafamidis in non‐Val30Met patients with transthyretin familial amyloid polyneuropathy, this… Expand
Review
2017
Review
2017
The endoplasmic reticulum: A hub of protein quality control in health and disease
Abstract One third of the eukaryotic proteome is synthesized at the endoplasmic reticulum (ER), whose unique properties provide a… Expand
  • table 1
Highly Cited
2016
Highly Cited
2016
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
Abstract Transthyretin hereditary amyloid polyneuropathy, also traditionally known as transthyretin familial amyloid… Expand
Review
2016
Review
2016
Current and future treatment of amyloid diseases
There are more than 30 human proteins whose aggregation appears to cause degenerative maladies referred to as amyloid diseases or… Expand
Highly Cited
2013
Highly Cited
2013
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2013
Highly Cited
2013
Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, efficacy, and safety of tafamidis in… Expand
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 2
2013
2013
Tafamidis (Vyndaqel): A Light for FAP Patients
Slowing FAP progression: Tafamidis meglumine is a small molecule capable of stabilizing the transthyretin (TTR) tetramer… Expand
Highly Cited
2012
Highly Cited
2012
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
The transthyretin amyloidoses (ATTR) are invariably fatal diseases characterized by progressive neuropathy and/or cardiomyopathy… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2012
Review
2012
TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients
Familial amyloid polyneuropathy (FAP) is a rare condition caused by mutations of the transthyretin (TTR) gene and it is generally… Expand
  • table 2
  • figure 1
  • figure 2
Review
2011
Review
2011
Familial amyloid polyneuropathy
Familial amyloid polyneuropathies (FAPs) are a group of life-threatening multisystem disorders transmitted as an autosomal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE